齐拉西酮结合丙戊酸钠治疗精神分裂症患者的疗效分析及对血清BDNF、GDNF水平的影响  

Analysis of the Efficacy of Ziprasidone Combined with Sodium Valproate in the Treatment of Schizophrenia and Its Effect on Serum BDNF and GDNF Levels

作　　者：陈鸣 CHEN Ming(Pharmacy of the Third People's Hospital of Dongtai City,Dongtai,Jiangsu Province,224200 China)

机构地区：[1]江苏省东台市第三人民医院药房,江苏东台224200

出　　处：《系统医学》2020年第23期165-167,共3页Systems Medicine

摘　　要：目的探讨精神分裂症患者采用齐拉西酮结合丙戊酸钠治疗的疗效观察及对血清脑源性神经营养因子(BDNF)、胶质源性神经营养因子(GDNF)水平的影响。方法选取2018年3月—2020年2月于该院治疗的90例精神分裂症患者,采用随机数字表法分为两组。对照组45例患者口服齐拉西酮治疗,观察组45例患者口服齐拉西酮+丙戊酸钠治疗。对比两组临床疗效、BDNF、GDNF水平和不良反应。结果观察组临床总有效率(95.56%)高于对照组(82.22%),差异有统计学意义(χ^2=4.050,P=0.044)。观察组治疗2个月后BDNF(13.78±2.08)ng/mL、GDNF(562.49±148.53)ng/mL,高于对照组的(10.69±3.32)ng/mL、(498.63±141.28)ng/mL,差异有统计学意义(t=5.291、2.090,P<0.05)。对照组不良反应发生率为11.11%,与观察组的6.67%相比,差异无统计学意义(χ^2=0.137,P=0.711)。结论精神分裂症患者应用齐拉西酮结合丙戊酸钠治疗效果较佳,能够提高BDNF、GDNF水平,且无严重不良反应,安全性较高,利于患者预后。Objective To investigate the therapeutic effect of ziprasidone combined with sodium valproate in patients with schizophrenia and its effect on serum brain-derived neurotrophic factor(BDNF)and glial-derived neurotrophic factor(GDNF)levels.Methods A total of 90 patients with schizophrenia treated in the hospital from March 2018 to February 2020 were selected and divided into two groups by random number table.45 patients in the control group were treated with ziprasidone orally,and 45 patients in the observation group and adverse reaction were treated with ziprasidone and sodium valproate.The clinical efficacy,BDNF and GDNF levels were compared between the two groups.Results The total clinical effective rate of the observation group(95.56%)was higher than that of the control group(82.22%),and the difference was statistically significant(χ^2=4.050,P=0.044).After 2 months of treatment in the observation group,BDNF(13.78±2.08)ng/mL and GDNF(562.49±148.53)ng/mL were higher than those of the control group(10.69±3.32)ng/mL and(498.63±141.28)ng/mL,the difference was statistically significant(t=5.291,2.090,P<0.05).The incidence of adverse reactions in the control group was 11.11%,which was not statistically significant compared with 6.67%in the observation group(χ^2=0.137,P=0.711).Conclusion Ziprasidone combined with sodium valproate has a better therapeutic effect in patients with schizophrenia.It can increase the levels of BDNF and GDNF without serious adverse reactions.It is safe and beneficial to the prognosis of patients.

关 键 词：精神分裂症 齐拉西酮 丙戊酸钠 临床疗效 脑源性神经营养因子 胶质源性神经营养因子 

分 类 号：R59[医药卫生—内科学]